Search company, investor...
Search
Akoya Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

akoyabio.com

Founded Year

2015

Stage

IPO | IPO

Total Raised

$87M

Date of IPO

4/16/2021

Market Cap

0.41B

Stock Price

10.91

About Akoya Biosciences

Akoya Biosciences (NASDAQ: AKYA) offers comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and other immune system or neurological disorders.

Akoya Biosciences Headquarters Location

100 Campus Drive 6th Floor

Menlo Park, California, 01762,

United States

855-896-8401

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Akoya Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Akoya Biosciences is included in 5 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,114 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

B

Biopharma Tech

838 items

Akoya Biosciences Patents

Akoya Biosciences has filed 12 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/3/2019

4/19/2022

Microscopy, Spectroscopy, Histopathology, Molecular biology, Luminescence

Grant

Application Date

5/3/2019

Grant Date

4/19/2022

Title

Related Topics

Microscopy, Spectroscopy, Histopathology, Molecular biology, Luminescence

Status

Grant

Latest Akoya Biosciences News

ViQi, Inc. Announces Pascal Bamford, Ph.D. and Timothy Spicer, Ph.D. Have Joined the Board of Directors and Scientific Advisory Board, Respectively

Sep 16, 2022

Share ViQi, Inc, a California cloud-based image analysis company specializing in using artificial intelligence for the scientific discovery process, is excited to announce the appointment of Pascal Bamford, Ph.D. to the board of directors and Timothy Spicer, Ph.D. as the inaugural member of the scientific advisory board. Pascal Bamford, Ph.D., is senior vice president of research and development and laboratory operations at Akoya Biosciences and brings his expertise in image analysis, software development and clinical systems implementation. Dr. Bamford has a PhD in cell image analysis from the University of Queensland, Australia and has spent his career applying advanced technologies to cancer diagnostics at companies such as Roche, Genomic Health and Exact Sciences. Pascal’s insights into the wealth of opportunities for the ViQi platform and applications are invaluable to the company’s future direction. Timothy Spicer, Ph.D. is a Research Professor and senior scientific director at UF Scripps Biomedical Research and of the current President of the board of directors at Society of Laboratory Automation & Screening (SLAS). Dr. Spicer brings with him extensive knowledge of High Throughput Screening systems and technology development, over 30 years of drug discovery experience, 100+ publications and multiple patents. Tim’s understanding of the automation and how High Content Analysis fits into the HTS process and its current needs and limitations, will help to navigate what AI solutions ViQi will focus on. “We are thrilled to get the advice and guidance from both Tim and Pascal. Their depth of understanding of these markets, the unresolved problems, the future vision and business strategy will be crucial in maximizing ViQi’s impact globally,” said Kathy Yeung , ViQi CEO. Related Posts Dr. Bamford commented, “The application of machine learning for new scientific discoveries and robust application deployment is without question. A key challenge has been the ability to seamlessly and efficiently manage the discovery to implementation cycle in a scalable, integrated and traceable fashion. The ViQi team have built an artificial intelligence platform and toolset that greatly accelerates this cycle and has enormous potential to drive innovation across many fields and industries. I am honored and excited to contribute to ViQi’s impactful mission.” Dr. Spicer also added, “I have personally experienced the power of High Throughput Screening and automation which has afforded us many critical discoveries, providing leads that ultimately have become live changing drugs. It’s also always nice to play in the intersection of science and technology especially when something as effectual as AI comes around. It’s true that traditional HTS generates lots of valuable data which we deal with in many beneficial ways, but we are still limited by what we perceive is the utility of the data. Today, we see so many more imaging applications in the HTS environment that output such eloquent data that, frankly, we need better analysis tools to help us interpret that data.”

Akoya Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Akoya Biosciences Rank

  • When was Akoya Biosciences founded?

    Akoya Biosciences was founded in 2015.

  • Where is Akoya Biosciences's headquarters?

    Akoya Biosciences's headquarters is located at 100 Campus Drive, Menlo Park.

  • What is Akoya Biosciences's latest funding round?

    Akoya Biosciences's latest funding round is IPO.

  • How much did Akoya Biosciences raise?

    Akoya Biosciences raised a total of $87M.

  • Who are the investors of Akoya Biosciences?

    Investors of Akoya Biosciences include Paycheck Protection Program, Telegraph Hill Partners, Agilent Technologies, Innovatus Capital Partners and Piper Jaffray Merchant Banking.

  • Who are Akoya Biosciences's competitors?

    Competitors of Akoya Biosciences include Lunaphore Technologies.

You May Also Like

RareCyte Logo
RareCyte

RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood. RareCyte is dedicated to bringing its technology to Life Sciences research, drug development, and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular disease.

Lunaphore Technologies Logo
Lunaphore Technologies

Lunaphore Technologies has developed a tissue diagnostics platform, primarily for analysis and classification of tumors. The platform is based on a microfluidic chip technology that allows fine-tuning of such diagnostic assays and increases speed and accuracy.

Fluidigm Logo
Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets microfluidic systems to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. Fluidigm's proprietary microfluidic systems consist of instruments and consumables, including 18 different commercial integrated fluidic circuits for nucleic acid analysis, and three families of assay chemistries. These systems are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.